Fidelity Select Biotechnology Portfolio Gross Profit

As of the most recent data (September 2023), FBIOX shows a gross profit of $9.9M. That compares with $9.3M in the prior-year period — up 6.6% year over year. That is below the sector sector average of $790M. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, FBIOX's gross profit is now $9.9M (was $9.3M) — a 6.6% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Fidelity Select Biotechnology Portfolio is outperforming or lagging.

The its sector sector average gross profit is about $790M. Fidelity Select Biotechnology Portfolio is at $9.9M, which is lower that average. That is roughly 98.7% below the sector mean. Use the comparison chart on this page to see how FBIOX stacks up against individual peers as well.

Tracking FBIOX's gross profit over time shows whether Fidelity Select Biotechnology Portfolio is scaling, shrinking, or reshaping that part of the business. The current reading is $9.9M That compares with $9.3M in the prior-year period — up 6.6% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this gross profit page, Stockcircle has Fidelity Select Biotechnology Portfolio's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect gross profit (currently $9.9M) with ownership activity and broader fundamentals.